Completed PHASE3 INTERVENTIONAL 1-arm NCT01395147

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

An Open-label, Long-Term Extension Study to Assess the Safety and Efficacy of Lu AA21004 in Patients With Major Depressive Disorder (Extension to Lu AA21004/CCT-003 Study)

Sponsor: Takeda

Conditions Major Depressive Disorder

Interventions Lu AA21004

Updated 6 times since 2017 Last updated: Nov 2, 2013 Started: Jul 31, 2011 Primary completion: May 31, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Major Depressive Disorder and is currently completed. Takeda leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amagasaki-shi, Japan , Anan-shi, Japan , Annaka-shi, Japan , Fujioka-shi, Japan , Fujisawa-shi, Japan , Fukaya-shi, Japan , Fukuoka, Japan , Hachioji-shi, Japan , Hatsukaichi-shi, Japan , Hiroshima, Japan and 21 more locations